RecruitingNot ApplicableNCT05783271

Validity of Parametric MRI Using VIRADS

Validity of Parametric MRI Using VIRAD Scoring in the Diagnosis of Cancer Bladder

Sponsor

Assiut University

Enrollment

58 participants

Start Date

Dec 1, 2025

Study Type

INTERVENTIONAL

Conditions

Bladder Cancer

Summary

Our aim in this prospective study is to evaluate the validity of the non-contrast biparametric MRI (bp-MRI), including T2-WI and DWI sequences, and the availability of an alternative to the mp-MRI, for the muscle invasiveness assessment of bladder cancer using VIRAD scoring in both techniques.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is testing the validity of a specialized MRI scoring system called VI-RADS (Vesical Imaging-Reporting and Data System) for assessing bladder cancer. The goal is to determine whether this MRI-based approach can accurately predict how deeply the cancer has grown into the bladder wall, which is important for determining the best treatment. **You may be eligible if:** - You are a patient suspected of having bladder cancer based on clinical examination, imaging, or tissue biopsy - You are any age - You are of any sex **You may NOT be eligible if:** - You have significantly impaired kidney function (high creatinine levels) that would make contrast-enhanced MRI risky - You have a contraindication to MRI, such as a pacemaker or cochlear implant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTGadolinium

All patients will be subjected to : MRI examinations on a 1.5-T MRI system in the supine position by using a 16-channel pelvic phased-array coil. The MRI proto col includes the following sequences: unenhanced axial T1-WI, high-resolution three planes (axial, coronal, and sagittal) T2-WI, axial DWI with b values of 0, 800, and 1600 s/mm2, axial DCE T1-WI with three-dimensional (3D) high temporal resolution. In all sequences, the small field of view (FOV) was used with the scope of viewing the entire bladder, proximal urethra, distal ureteral orifices, and adjacent pelvic organs. Gadopentetate dimeglumine (Gadovist, 0.1 ml/kg body weight) is administered at a rate of 2 ml/s using a power injector.